Trial Profile
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2021
Price :
$35
*
At a glance
- Drugs Simvastatin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms STATCOPE
- 27 Feb 2021 Results(n=227) assessing the effects of simvastatin on TF and coagulation biomarkers, published in the Journal of Thrombosis and Haemostasis
- 21 Oct 2013 Planned End Date changed from 1 Dec 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.